Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Mezagitamab placebo-matching injection administered sc
DRUG
2 trials
Sponsors
Takeda Development Center Americas Inc.
Conditions
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)
Late antibody mediated rejection (AMR)
Phase 2
A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Mezagitamab (TAK-079) in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
Not yet recruiting
CTIS2026-526239-20-00
Takeda Development Center Americas Inc.
Late antibody mediated rejection (AMR)
Target: 8
Updated: 2026-10-20
Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy
Not yet recruiting
CTIS2025-520825-19-00
Takeda Development Center Americas Inc.
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)
Target: 83
Updated: 2025-11-05